Erming Tian

OverviewAI-generated summary

Erming Tian's research primarily investigates multiple myeloma, a hematologic malignancy. His work focuses on identifying genetic and clinical factors associated with patient outcomes. Recent publications explore the prognostic significance of minimal residual disease (MRD) negativity and persistence in bone marrow, as well as the clinical implications of specific chromosomal abnormalities, such as deletion of 1p13.3 and gain of 1q21, in multiple myeloma.

Further research by Tian examines the role of mutations in genes like BRAF and DIS3 in predicting adverse outcomes in patients with multiple myeloma. He also investigates the potential for overcoming adverse metaphase cytogenetics by incorporating specific chemotherapies, such as bortezomib and thalidomide, into treatment regimens for patients undergoing fractionated melphalan transplants. His work also includes exploring phenotypic markers for disease progression in monoclonal gammopathy of unknown significance using eight-color flow cytometry.

Tian has a notable publication record, with 101 total publications and over 5,300 citations, reflected in his h-index of 31. He is recognized as a highly cited researcher. Key collaborators include Shmuel Yaccoby, Michele Cottler-Fox, Clyde Bailey, and Susan Panozzo, all from the University of Arkansas for Medical Sciences, with whom he has co-authored multiple publications.

Metrics

• h-index: 31
• Publications: 101
• Citations: 5,348